ResApp Health Limited announced that it has recruited ten patients on the first day of its pilot study for the collection of cough sounds from patients with suspected COVID-19 in India. ResApp aims to use this data to develop a smartphone-based algorithm to instantly screen for COVID-19 and monitor disease progression. Patient recruitment follows approval from an institutional review board that assessed and approved the ethical design of the study. The study is registered on Clinical Trials Registry India (CTRI/2021/09/036581). ResApp has engaged Triomics, a clinical trial company based in India, to complete the study. The study will collect cough sounds, symptoms, medical history and a COVID-19 polymerase chain reaction (PCR) test result from each participant. The multi-site study will recruit a total of 220 participants across two study arms: 120 individuals who present for outpatient COVID-19 PCR testing and 100 individuals who are COVID-19 positive and are inpatients at a study site. Inpatients will provide cough sound samples at multiple times during their hospital stay. Study recruitment is expected to be complete by the end of October. ResApp is using data collected in this clinical study, as well as its two US studies, to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone.